v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating Expenses        
Research and development expenses $ 1,661,646 $ 2,287,525 $ 5,696,691 $ 5,556,694
General and administrative expenses 1,827,197 1,137,328 4,589,925 3,759,781
Operating Loss (3,488,843) (3,424,853) (10,286,616) (9,316,475)
Other Income, net 52,270 40,150 81,720 195,065
Net Loss $ (3,436,573) $ (3,384,703) $ (10,204,896) $ (9,121,410)
Net Loss per Common Share - Basic $ (0.07) $ (1.03) $ (0.41) $ (3.13)
Net Loss per Common Share - Diluted $ (0.07) $ (1.03) $ (0.41) $ (3.13)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic 47,525,522 3,275,998 24,838,859 2,909,941
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted 47,525,522 3,275,998 24,838,859 2,909,941

Source